

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal617mxb

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files
NEWS 3 Feb 06 Engineering Information Encompass files have new names
NEWS 4 Feb 16 TOXLINE no longer being updated
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7 May 07 DGENE Reload
NEWS 8 Jun 20 Published patent applications (A1) are now in USPATFULL
NEWS 9 JUL 13 New SDI alert frequency now available in Derwent's
DWPI and DPCI

NEWS EXPRESS July 11 CURRENT WINDOWS VERSION IS V6.0b,
CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2001
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:06:42 ON 24 JUL 2001

=> file mebase biosis medline uspatfull caplus

'MEBASE' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):embase

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'EMBASE' ENTERED AT 16:06:58 ON 24 JUL 2001

COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 16:06:58 ON 24 JUL 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'MEDLINE' ENTERED AT 16:06:58 ON 24 JUL 2001

FILE 'USPATFULL' ENTERED AT 16:06:58 ON 24 JUL 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 16:06:58 ON 24 JUL 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

=> s artrodar

L1 11 ARTRODAR

=> dup rem

ENTER L# LIST OR (END):11

PROCESSING COMPLETED FOR L1

L2 11 DUP REM L1 (0 DUPLICATES REMOVED)

=> s 12 and py<2000

2 FILES SEARCHED...

L3 10 L2 AND PY<2000

=> d 13 1-10 kwic ab bib

L3 ANSWER 1 OF 10 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
SO Giornale Italiano di Ricerche Cliniche e Terapeutiche, (1992) 13/6
(151-156).
ISSN: 0393-5957 CODEN: GIRTEW
CN **(1) Artrodar**
AN 93036250 EMBASE
DN 1993036250
TI [Evaluation of clinical effectiveness and tolerability of diacerhein
retard in knee arthrosis].
VALUTAZIONE DELL'EFFICACIA CLINICA E DELLA TOLLERABILITA DI DIACEREINA IN
FORMULAZIONE RITARDO NEL TRATTAMENTO DELLA GONARTROSI.
AU Paresce E.; Angelini M.; Carabba M.
CS Via Lambro, 36,20090 Opera, Italy
SO Giornale Italiano di Ricerche Cliniche e Terapeutiche, (1992) 13/6
(151-156).
ISSN: 0393-5957 CODEN: GIRTEW
CY Italy
DT Journal; Article
FS 031 Arthritis and Rheumatism
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA Italian
SL Italian; English

L3 ANSWER 2 OF 10 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
SO Minerva Medica, (1987) 78/6 (411-413).
CODEN: MIMEAO
CN **Artrodar**
AB The potential capacity of diacerheine (DAR), a new drug known to have no
anti-prostaglandin effect and therefore a different action mechanism from
the standard non-steroid anti-inflammatory drugs, to cause damage to the

gastroduodenal mucosa was compared with that of a well-known NSAID, naproxene. Gastroscopic examination of 10+10 patients before and 4 weeks after treatment showed that DAR produced endoscopic lesions without subjective symptoms in 10% of the patients whereas naproxene produced lesions of varying size in 50%, with or without symptoms.

AN 87131234 EMBASE
DN 1987131234
TI [Endoscopic assessment of the effects of diacereine and naproxene on the gastroduodenal mucosa].
VALUTAZIONE ENDOSCOPICA DEGLI EFFETTI DELLA DIACEREINA E DEL NAPROSSENE SULLA MUCOSA GASTRODUODENALE.

AU Bianchi Porro G.; Ardizzone S.; Caruso I.; Montrone F.
CS Ospedale 'L. Sacco', Servizio di Gastroenterologia ed Endoscopia Digestiva, Milano, Italy
SO Minerva Medica, (1987) 78/6 (411-413).
CODEN: MIMEOA
CY Italy
DT Journal
FS 037 Drug Literature Index
048 Gastroenterology
038 Adverse Reactions Titles
LA Italian
SL English

L3 ANSWER 3 OF 10 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
SO Minerva Medica, (1987) 78/3 (179-185).
CODEN: MIMEOA
CN **Artrodar**
AB 71 patients with variously located osteoarthritis or primary fibromyalgic syndrome were treated with oral diacereine (DAR). The case series was accumulated in successive periods and may be divided into three groups.

An 'open' test of DAR (100 mg/die for 4 weeks) was conducted on the first group of 31 arthrotic patients. On the second group of 20 other arthrotic patients a 'double-blind, cross-over' test was carried out using DAR (100 mg/die) and naproxene (500 mg/die) both for 2 weeks. The third group of 20 patients with fibromyalgia was treated with DAR alone: 100 mg/die 5 days a week for 12 weeks. The efficacy of the treatment was judged on the basis of the following parameters: rest pain, pressure pain, pain on active and passive movement, and functional limitation. In the first group a positive therapeutic effect was noted in 20 cases (68.9%). There were side effects (moderate diarrhea) in 3 patients, 2 of whom suspended treatment. In the second group, DAR and naproxene had an almost identical effect. However, 7 patients (36.8%) expressed a preference for DAR, 9 (47.4%) expressed no preference and only 3 (15.8%) preferred naproxene. Side effects were encountered in 3 patients treated with naproxene (2 cases of epigastralgia and pyrosis and 1 case of dyspnea, so marked as to require suspension of treatment) and in 3 treated with DAR (moderate diarrhea). In the third group, a positive therapeutic effect was noted in 68.4% of the patients with fibromyalgia with a 15% incidence of side effects consisting of slight abdominal pain (diarrhea caused suspension of treatment in 1 case only). Blood chemical parameters were studied in all three groups and no alterations attributable to the treatment were found. The obtained results suggest that the new drug is effective and well tolerated in the envisaged indications.

AN 87102507 EMBASE
DN 1987102507
TI [Diacereine, an 'original' approach to the treatment of degenerative and/or extra-articular rheumatism].

DIACEREINA: UN APPROCCIO 'ORIGINALE' NEL TRATTAMENTO DEI REUMATISMI
DEGENERATIVI E/O EXTRA-ARTICOLARI.

AU Carrabba M.; Mele G.; Chevallard M.; Angelini M.
CS Cattedra di Reumatologia dell'Universita, Istituto Ortopedico 'G. Pini',
Milano, Italy
SO Minerva Medica, (1987) 78/3 (179-185).
CODEN: MIMEAO
CY Italy
DT Journal
FS 038 Adverse Reactions Titles
037 Drug Literature Index
031 Arthritis and Rheumatism
030 Pharmacology
LA Italian
SL English

L3 ANSWER 4 OF 10 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
TI A controlled study in the treatment of osteoarthritis with diacetylrhein
(
Artrodar.RTM.).
SO Current Therapeutic Research - Clinical and Experimental, (1982) 31/3 I
(408-412).
CODEN: CTCEA
CN **Artrodar**
AB A controlled double-blind clinical evaluation of diacetylrhein
(Atrodar.RTM.) versus placebo in the treatment of osteoarthritis of the
hip or knee was conducted in 20 patients. Clinical response was assessed
in terms of symptomatic relief, functional change, and objective
measurements. The drug, an anti-inflammatory with a mechanism of action
different from that of N.S.A.I.D., was significantly effective both at
the
8 dose of 50 mg/day (first 4 weeks) and at the dose of 100 mg/day (further
weeks), with minimum side effects. The results were classified as
excellent or good in 17 of the 20 patients treated (85%).
AN 82129154 EMBASE
DN 1982129154
TI A controlled study in the treatment of osteoarthritis with diacetylrhein
(
Artrodar.RTM.).
AU Lingetti M.; D'Ambrosio P.L.; Di Grezia F.; et al.
CS Div. Geriat., Civ. Hosp., Avellino, Italy
SO Current Therapeutic Research - Clinical and Experimental, (1982) 31/3 I
(408-412).
CODEN: CTCEA
CY United States
DT Journal
FS 038 Adverse Reactions Titles
037 Drug Literature Index
020 Gerontology and Geriatrics
LA English

L3 ANSWER 5 OF 10 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
TI Clinical, biological and gastric fibroscopic tolerance of a new
non-steroidal anti-inflammatory analgesic, diacetylrhein (**Artrodar**
).
SO Drugs under Experimental and Clinical Research, (1980) 6/1 (53-64).
CODEN: DECRDP
CN **Artrodar**
AN 81000450 EMBASE
DN 1981000450
TI Clinical, biological and gastric fibroscopic tolerance of a new
non-steroidal anti-inflammatory analgesic, diacetylrhein (**Artrodar**
).
AU Neuman M.
CS Hop. Cochin, Paris, France

SO Drugs under Experimental and Clinical Research, (1980) 6/1 (53-64).
CODEN: DECRDP
CY Switzerland
DT Journal
FS 037 Drug Literature Index
030 Pharmacology
031 Arthritis and Rheumatism
LA English

L3 ANSWER 6 OF 10 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.

SO Drugs of the Future, (1979) 4/6 (445-447).
CODEN: DRFUD4

CN Sf 277; **Artrodar**
AN 79218845 EMBASE
DN 1979218845
TI SF-277. Antirheumatic.
AU Neuman M.

CS Spain
SO Drugs of the Future, (1979) 4/6 (445-447).
CODEN: DRFUD4

CY Spain
DT Journal
FS 037 Drug Literature Index
LA English

L3 ANSWER 7 OF 10 USPATFULL

PI US 5986129 19991116 <--

SUMM Diacerhein is commercially available in the form of pharmaceutical preparations, such as **Artrodar** .sup.R.

AB The following description sets forth a process for producing rhein, diacerhein and other diacyl derivatives thereof, which comprises the following steps: treatment of a diphenylketone ##STR1## in which

R.sub.1 is --OR', --NR'R", --SR', where R' and R" are H, an alkyl or aromatic group; R.sub.2 is H or a protective group, R.sub.3 is --OH or C.sub.1 -C.sub.4 alkyl, with an acid or superacid to give a 1-aminoanthraquinone derivative, diazotisation, replacement of the --NH.sub.2 group by --OH, optional removal of the protective group, and acylation.

AN 1999:146828 USPATFULL
TI Process for producing rhein and diacerhein
IN Di Napoli, Guido, Collonge-Bellerive, Switzerland
PA Laboratoire Medidom S.A., Geneve, Switzerland (non-U.S. corporation)
PI US 5986129 19991116 <--
AI US 1997-903663 19970731 (8)
PRAI IT 1996-MI1656 19960731

DT Utility
FS Granted
EXNAM Primary Examiner: Lambkin, Deborah C.
LREP Hedman, Gibson & Costigan
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 769

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 10 USPATFULL

PI US 5670695 19970923 <--

SUMM Diacerein is a compound possessing antiarthritic activity, available under various trademarks, e.g. **Artrodar**.RTM. (The Merck Index, 11th Ed., 1989, Merck & Co., Inc., Rahaway, N.J., USA, 2939).

AB The present invention relates to a process for the preparation of 1,8-diacetoxy-3-carboxyanthraquinone, also known as diacerein, via

aloin
acetylation, oxidation of the acetylated product, and purification of the raw diacerein obtained by means of crystallization from

2-methoxyethanol or N,N-dimethylacetamide and optionally by dissolution of the corresponding salt with triethylamine in methylene chloride, followed by removal of the insoluble residue.

AN 97:86801 USPATFULL
TI Process for the preparation of diacerein
IN Di Napoli, Guido, Collonge-Bellerive, Switzerland
PA Laboratoire Medidom S.A., Geneva, Switzerland (non-U.S. corporation)
PI US 5670695 19970923 <--
AI US 1995-376722 19950123 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose G.; Assistant Examiner: Puttlitz, Jr., Karl
J.
LREP Kenyon & Kenyon
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 547
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 10 USPATFULL
PI US 5627173 19970506 <--
DETD . . . was unaltered. The standard used was diacerein which is used as
an osteoarthritis remedy in Italy under the proprietary name
Artrodar.
AB Phosphonoacetic acid derivatives and their use for treating degenerative
joint disorders Compounds of the formula I ##STR1## are suitable for producing pharmaceuticals for the treatment and prophylaxis of degenerative joint disorders, of rheumatic disorders accompanied by cartilage breakdown, such as rheumatoid arthritis, joint trauma and chondrolysis as a consequence of prolonged immobilization of the joint, of inflammations, septic shock, disorders with impaired leukocyte adhesion, disorders caused by an elevated concentration of tumor necrosis factor alpha, such as cachexia or Crohn's disease.

AN 97:38516 USPATFULL
TI Phosphonoacetic acid derivatives and their use for treating degenerative
joint disorders
IN Graeve, Rolf, Taunustein, Germany, Federal Republic of
Thorwart, Werner, Hochheim, Germany, Federal Republic of
Raiss, Ruth, Frankfurt, Germany, Federal Republic of
Weithmann, Klaus U., Hofheim, Germany, Federal Republic of
M ullner, Stefan, Hochheim, Germany, Federal Republic of
PA Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic
of (non-U.S. corporation)
PI US 5627173 19970506 <--
AI US 1996-590300 19960123 (8)
PRAI DE 1995-19502209 19950125
DT Utility
FS Granted
EXNAM Primary Examiner: Richter, Johann; Assistant Examiner: Ambrose, Michael G.
LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1962
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 10 USPATFULL
PI US 4950687 19900821 <--
DETD 2 ml of an aqueous solution containing 25 mg of potassium diacetyl
rhein

salts (**ARTRODAR K.RTM.**) were injected in the sinovial liquid of 20 patients affected by gonarthrosis once a week for five times.

DETD The same quantity of the aqueous solution used in example 7 and containing the same amount of **ARTRODAR K.RTM.** was administered in the sinovial liquid of other 20 patients affected by gonarthrosis once a week for 5 times.

DETD The same quantity of the aqueous solution used in example 7 and containing the same amount of **ARTRODAR K.RTM.** was administered in the sinovial liquid of other 20 patients affected by gonarthrosis once a week for 6 times.

DETD The same quantity of the aqueous solution used in example 7 and containing the same amount of **ARTRODAR K.RTM.** was administered on the sinovial liquid of other 8 patients affected by gonarthrosis once a week for 5 times.

DETD COMPARATIVE EXAMPLE 20 patients affected by gonarthrosis were treated with diacetyl rhein (**ARTRODAR.RTM.**) with the following posology 1.times.25 mg capsules /day for 4 weeks, and then 1.times.2 50 mg capsules/ day for further. . . .

AB A therapeutic treatment for the athrosis diseases comprising administering by intraarticular route from 1 to 5 ml of an aqueous solution containing from 10 to 50 mg of a diacetyl rhein salt having formula (I): ##STR1## wherein M represents an alkali or an earth alkali metal or the residue of an organic base.

The diacetyl rhein salts administered by intraarticular route exhibit higher pharmacological activity than the corresponding diacetylrhein administered orally.

AN 90:65574 USPATFULL

TI Diacetylrhein salts and their therapeutical use in the treatment of arthrosis

IN Dall'Asta, Leone, Pavia, Italy
Coppi, Germano, Buccinasco, Italy
Scevola, Mario Ercole, Milan, Italy

PA Proter S.p.A., Opera, Italy (non-U.S. corporation)

PI US 4950687 19900821 <--

AI US 1989-379787 19890717 (7)

RLI Continuation-in-part of Ser. No. US 1987-45817, filed on 4 May 1987, now abandoned

PRAI IT 1986-20298 19860502

DT Utility

FS Granted

EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Covington, Raymond

LREP Cushman, Darby & Cushman

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 213

CAS INDEXING IS AVAILABLE FOR THIS PATENT.